The FDA has cleared the investigational new drug application for STAR-0310 as a potential treatment for atopic dermatitis and other diseases, Astria Therapeutics announced in a press release. STAR-0310 is part of the OX40 antagonist class of medications which has shown efficacy in treating AD and may do so in other diseases as well, such as in hidradenitis suppurativa.
The AAAAI has allergy-free play dough recipes for your children, students or scouting projects.
The U.S. Preventive Services Task Force released a draft recommendation that women aged 21 to 65 years be regularly screened for cervical cancer.According to the…
Global increases in life expectancy have been accompanied by a similar rise in the number of years living with the effects of disease. This difference…
WASHINGTON — Delaying methotrexate initiation for 1 month after pneumococcal vaccination improves humoral response in patients with rheumatoid arthritis, according to data presented at ACR…
SAN ANTONIO — The addition of pyrotinib to first-line trastuzumab and docetaxel improved PFS among patients with HER2-positive metastatic breast cancer, according to study results…
Following backlash, Anthem Blue Cross Blue Shield stalled its policy change that would have put a time limit on coverage for anesthesiology services during surgery…
SAN ANTONIO — One year of adjuvant olaparib after standard treatment improved outcomes compared with placebo among patients with high-risk BRCA-mutated breast cancer, according to…
SAN ANTONIO — Imlunestrant alone or as part of combination therapy extended PFS for certain patients with advanced breast cancer resistant to hormone therapy, according…
Mast cells act as “signal converters,” translating immunological and tissue signals into host-protective behaviors. They sense antigen and possibly toxins driving avoidance behavior, which can…
SAN ANTONIO — Risk-reducing surgery appeared linked with improved outcomes among BRCA mutation carriers diagnosed with early breast cancer, according to study results presented at…
